← Leaderboards

Carl W White

National Jewish Health

Google Scholar ↗PubMed ↗ORCID ↗

$29,966,481

Attributed

$30,466,480

Total exposure

25

Grants

20

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.2M · FY2005–21

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

Funding mix

By agency

NIH$67,672,158 · 27

By mechanism

U54$60,511,056 · 15

P50$2,370,573 · 1

R01$2,146,201 · 2

U01$1,483,047 · 1

RC1$999,999 · 1

P51$161,282 · 6

Top collaborators

Susan D Reynolds2 shared

Others in their field

Top investigators on “Lung”

Sonia M Thomas · Research Triangle Institute$701,865,642
Tracy L Nolen · Research Triangle Institute$474,487,152
David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
Chanza Baytop · Westat, Inc.$271,217,917
Richard K. Wilson · Washington University$201,818,043
Walter John Curran · Thomas Jefferson University$112,093,071

Research focus

LungInjuryMustard GasProgramsLung InjuryBaseGasesResearch PersonnelAntioxidantsAreaBreathingLaboratoriesToxic EffectRattusIn VivoInflammationLeadAcuteEventAnalogMemberExposure ToReportingColorado

Grant awards (124)

Effect of vaping on COVID-19 infection$182,367

U54 · FY2021 · ES · contact PI

Development of antidotes for toxic gases$3,214,723

U54 · FY2020 · ES · contact PI

Fibrinolytic therapies for methyl isocyanate$1,055,271

U54 · FY2020 · ES · contact PI

Administrative Core$478,075

U54 · FY2020 · ES · contact PI

Educational Core$149,508

U54 · FY2020 · ES · contact PI

Development of antidotes for toxic gases$3,234,132

U54 · FY2019 · ES · contact PI

Fibrinolytic therapies for methyl isocyanate$1,306,308

U54 · FY2019 · ES · contact PI

Administrative Core$445,827

U54 · FY2019 · ES · contact PI

Educational Core$169,669

U54 · FY2019 · ES · contact PI

Development of antidotes for toxic gases$3,230,972

U54 · FY2018 · ES · contact PI

Fibrinolytic therapies for methyl isocyanate$871,068

U54 · FY2018 · ES · contact PI

Administrative Core$436,032

U54 · FY2018 · ES · contact PI

Educational Core$142,416

U54 · FY2018 · ES · contact PI

Development of antidotes for toxic gases$3,273,958

U54 · FY2017 · ES · contact PI

Fibrinolytic therapies for methyl isocyanate$877,918

U54 · FY2017 · ES · contact PI

Administrative Core$436,032

U54 · FY2017 · ES · contact PI

New Developments in Chemical Countermeasures: CounterACT 2018$150,000

U54 · FY2017 · ES · contact PI

Educational Core$142,416

U54 · FY2017 · ES · contact PI

Development of antidotes for toxic gases$3,435,426

U54 · FY2016 · ES · contact PI

Fibrinolytic therapies for methyl isocyanate$933,418

U54 · FY2016 · ES · contact PI

Administrative Core$418,112

U54 · FY2016 · ES · contact PI

Educational Core$142,416

U54 · FY2016 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$2,453,432

U54 · FY2015 · ES · contact PI

Educational core$754,354

U54 · FY2015 · ES · contact PI

Anticoagulant and fibrinolytic therapies for toxic inhaled chemical$642,320

U54 · FY2015 · ES · contact PI

Evaluation of novel therapies for vesicant skin toxicities$453,178

U54 · FY2015 · ES · contact PI

Catalytic antioxidant for toxic inhaled chemicals$323,523

U54 · FY2015 · ES · contact PI

Administrative core$149,982

U54 · FY2015 · ES · contact PI

Exposure core$130,075

U54 · FY2015 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$2,402,664

U54 · FY2014 · ES · contact PI

Educational core$720,975

U54 · FY2014 · ES · contact PI

Anticoagulant and fibrinolytic therapies for toxic inhaled chemical$636,378

U54 · FY2014 · ES · contact PI

Evaluation of novel therapies for vesicant skin toxicities$424,468

U54 · FY2014 · ES · contact PI

Catalytic antioxidant for toxic inhaled chemicals$342,976

U54 · FY2014 · ES · contact PI

Administrative core$149,497

U54 · FY2014 · ES · contact PI

Exposure core$128,370

U54 · FY2014 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$2,383,642

U54 · FY2013 · ES · contact PI

Educational core$722,951

U54 · FY2013 · ES · contact PI

Anticoagulant and fibrinolytic therapies for toxic inhaled chemical$619,998

U54 · FY2013 · ES · contact PI

Evaluation of novel therapies for vesicant skin toxicities$436,047

U54 · FY2013 · ES · contact PI

Catalytic antioxidant for toxic inhaled chemicals$333,525

U54 · FY2013 · ES · contact PI

Administrative core$146,548

U54 · FY2013 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$143,523

U54 · FY2013 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$130,000

U54 · FY2013 · ES · contact PI

Exposure core$124,573

U54 · FY2013 · ES · contact PI

Catalytic antioxidant for toxic inhaled chemicals$23,921

U54 · FY2013 · ES · contact PI

Anticoagulant and fibrinolytic therapies for toxic inhaled chemical$23,921

U54 · FY2013 · ES · contact PI

Evaluation of novel therapies for vesicant skin toxicities$23,921

U54 · FY2013 · ES · contact PI

Educational core$23,920

U54 · FY2013 · ES · contact PI

Administrative core$23,920

U54 · FY2013 · ES · contact PI

Exposure core$23,920

U54 · FY2013 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$2,130,518

U54 · FY2012 · ES · contact PI

Educational core$646,503

U54 · FY2012 · ES · contact PI

Anticoagulant and fibrinolytic therapies for toxic inhaled chemical$552,704

U54 · FY2012 · ES · contact PI

Evaluation of novel therapies for vesicant skin toxicities$392,498

U54 · FY2012 · ES · contact PI

Catalytic antioxidant for toxic inhaled chemicals$296,766

U54 · FY2012 · ES · contact PI

Administrative core$131,444

U54 · FY2012 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$128,000

U54 · FY2012 · ES · contact PI

Exposure core$110,603

U54 · FY2012 · ES · contact PI

Novel therapeutics for vesicants and toxic inhaled chemicals (U54)$2,540,289

U54 · FY2011 · ES · contact PI

Educational core$804,963

U54 · FY2011 · ES · contact PI

Anticoagulant and fibrinolytic therapies for toxic inhaled chemical$625,468

U54 · FY2011 · ES · contact PI

Administrative core$147,281

U54 · FY2011 · ES · contact PI

Exposure core$122,665

U54 · FY2011 · ES · contact PI

Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension$64,849

P50 · FY2011 · HL · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$1,588,569

U54 · FY2010 · ES · contact PI

Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension$591,764

P50 · FY2010 · HL · contact PI

Cell Based Therapy for Lung Disease$500,000

RC1 · FY2010 · HL

Thiols in sulfur mustard toxicity$387,781

U54 · FY2010 · ES · contact PI

Exposure$367,191

U54 · FY2010 · ES · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$197,794

U54 · FY2010 · ES · contact PI

Administration$84,560

U54 · FY2010 · ES · contact PI

Education$25,561

U54 · FY2010 · ES · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$1,563,803

U54 · FY2009 · ES · contact PI

Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension$585,029

P50 · FY2009 · HL · contact PI

Cell Based Therapy for Lung Disease$499,999

RC1 · FY2009 · HL

Thiols in sulfur mustard toxicity$372,470

U54 · FY2009 · ES · contact PI

Exposure$351,793

U54 · FY2009 · ES · contact PI

Lung epithelial cell survival signaling in ozone in cystic fibrosis and normals$309,849

R01 · FY2009 · ES · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$150,000

U54 · FY2009 · ES · contact PI

Administration$81,736

U54 · FY2009 · ES · contact PI

Education$25,042

U54 · FY2009 · ES · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$1,524,112

U54 · FY2008 · ES · contact PI

Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension$567,617

P50 · FY2008 · HL · contact PI

Thiols in sulfur mustard toxicity$358,174

U54 · FY2008 · ES · contact PI

Exposure$337,334

U54 · FY2008 · ES · contact PI

Lung epithelial cell survival signaling in ozone in cystic fibrosis and normals$309,849

R01 · FY2008 · ES · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$121,847

U54 · FY2008 · ES · contact PI

Administration$79,107

U54 · FY2008 · ES · contact PI

Education$24,565

U54 · FY2008 · ES · contact PI

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$22,649

P51 · FY2008 · RR · contact PI

HYPOXIA-INDUCIBLE FACTORS IN BPD$22,649

P51 · FY2008 · RR · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$1,484,634

U54 · FY2007 · ES · contact PI

Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension$561,314

P50 · FY2007 · HL · contact PI

Thiols in sulfur mustard toxicity$382,707

U54 · FY2007 · ES · contact PI

Lung epithelial cell survival signaling in ozone in cystic fibrosis and normals$316,171

R01 · FY2007 · ES · contact PI

Exposure$297,076

U54 · FY2007 · ES · contact PI

HYPOXIA-INDUCIBLE FACTORS IN BPD$60,030

P51 · FY2007 · RR · contact PI

Administration$52,279

U54 · FY2007 · ES · contact PI

Education$30,324

U54 · FY2007 · ES · contact PI

Novel antioxidant therapeutics for sulfur mustard toxicity (U54)$1,541,273

U54 · FY2006 · ES · contact PI

Thiols in sulfur mustard toxicity$372,976

U54 · FY2006 · ES · contact PI

Lung epithelial cell survival signaling in ozone in cystic fibrosis and normals$325,614

R01 · FY2006 · ES · contact PI

Exposure$298,555

U54 · FY2006 · ES · contact PI

Hypoxia-inducible factors bronchopulmonary dysplasia-BPD$238,068

U01 · FY2006 · HL · contact PI

Administration$129,943

U54 · FY2006 · ES · contact PI

Education$27,562

U54 · FY2006 · ES · contact PI

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$26,155

P51 · FY2006 · RR · contact PI

Lung epithelial cell survival signaling in ozone in cystic fibrosis and normals$333,450

R01 · FY2005 · ES

Hypoxia-inducible factors bronchopulmonary dysplasia-BPD$237,757

U01 · FY2005 · HL

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$21,090

P51 · FY2005 · RR

Hypoxia-inducible factors bronchopulmonary dysplasia-BPD$230,831

U01 · FY2004 · HL

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$5,516

P51 · FY2004 · RR

Hypoxia-inducible factors bronchopulmonary dysplasia-BPD$224,109

U01 · FY2003 · HL

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$3,193

P51 · FY2003 · RR

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$188,193

U01 · FY2002 · HL

ROLE OF HEXOKINASE IN LUNG ADAPTATION TO OXIDANT STRESS$187,245

R01 · FY2002 · HL

ROLE OF HEXOKINASE IN ADAPTATION TO OXIDANT STRESS$0

P01 · FY2002 · HL

ROLE OF HEXOKINASE IN LUNG ADAPTATION TO OXIDANT STRESS$184,883

R01 · FY2001 · HL

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$184,055

U01 · FY2001 · HL

ROLE OF HEXOKINASE IN ADAPTATION TO OXIDANT STRESS$0

P01 · FY2001 · HL

CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY$180,034

U01 · FY2000 · HL

ROLE OF HEXOKINASE IN LUNG ADAPTATION TO OXIDANT STRESS$179,140

R01 · FY2000 · HL

ROLE OF HEXOKINASE IN ADAPTATION TO OXIDANT STRESS$0

P01 · FY2000 · HL